ProBioGen, a complex biologics creation and production specialist, recently announced that its researchers have created an investigational Ebola virus vaccine in its proprietary, continuous Muscovy duck AGE1.CR.pIX cell line that is now progressing into clinical trials.
The new vaccine candidate is a modified vaccinia Ankara (MVA) Ebola Zaire vaccine. The earlier version of the vaccine was created under the leadership of Emergent BioSolutions, which ordered a 200-liter scale in order to supply the resources for its Phase 1 clinical trial.
The clinical trials, which are taking place at Jenner Institute of Oxford University in the U.K., shows that the vaccine may be effective in protecting people against Ebola.
“Production of the first-ever batch of MVA for a clinical trial using a cell line is a milestone in the development of this important vaccine technology,” Adrian Hill, director of Oxford’s Jenner Institute, said. “This new process, which will allow very large scale production, will be of value not only for Ebola prevention, but also for a wide range of other disease indications including malaria and tuberculosis vaccination.”
ProBioGen’s Chief Scientific Officer Volker Sandig said the AGE1.CR manufacturing platform offers shorter response times, full industrial bioreactor scalability and therefore much greater flexibility, compared to traditional vaccine production processes depending on embryonated chicken eggs.
“It is very satisfying to see that our broadly applicable vaccine production platform is instrumental to efficiently supply urgently needed human vaccines available to patients worldwide,” he said.